pfront autologous stem cell transplantation for primaly peripheral T cell lymphoma
Phase 2
- Conditions
- ALK-ngative Anaplastic large cell lymphoma(ALCL), Angioimmunoblastic T-cell lymphoma(AITL), Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)
- Registration Number
- JPRN-UMIN000028831
- Lead Sponsor
- Tosei General Hospital Department of Hematology and Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with uncontroled DM even by the usage of insulin Patients with uncontroled HT Patients with past histories of myocardial infarction, congestive heart failure, and unstable angina Patients with the Ejection Frction less than 50 percent Patients with active double cacer Patients with active infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival at 1 year after ASCT
- Secondary Outcome Measures
Name Time Method Overall survival at 2 years afer ASCT Overall response rate at day 100 after ASCT Adverse Events and treatment related mortality at day 100 afer ASCT engraftment ratio and hematopoetic recovery at day 50 after ASCT